Initial adjustments in the dosage and rest period of gemcitabine plus cisplatin therapy for patients with incurable biliary tract cancer based on baseline estimated glomerular filtration rate (eGFR) values may be crucial for treatment outcomes and th
Adjusting GC therapy based on baseline estimated glomerular eGFR may be pivotal for therapeutic benefits and renal function protection in patients with incurable BTC.
Authors
- Kazuki Nakamura (ORCID: https://orcid.org/0000-0003-1556-3263)
- Seiichi Tawara (ORCID: https://orcid.org/0009-0005-2482-5845)
- Takayuki Yakushijin
- Yuki Maegawa
- Takuo Yamai (ORCID: https://orcid.org/0000-0002-5448-4763)
- Takuya Inoue (ORCID: https://orcid.org/0000-0002-0365-3934)
- Tomeyoshi Masumoto
- Takeshi Shimizu (ORCID: https://orcid.org/0000-0002-3835-3536)
- Ryosuke Kiyota
- Tetsuro Miyazaki
- Hiroki Sugioka
- Shoichiro Kawai (ORCID: https://orcid.org/0000-0001-7590-8636)
- Kohei Kamizono
Institutions
- Osaka Prefectural Medical Center (JP)
- Osaka City General Hospital (JP)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/jgo-24-330
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57